Serum degradome markers for the detection of breast cancer

Journal of Proteome Research

Volumn 9, Issue 8, 2010, Pages 3781-3788

  Van Winden, Annemieke W J ^a,b   Van Den Broek, Irene ^c   Gast, Marie Christine W ^b,d   Engwegen, Judith Y M N ^b,e   Sparidans, Rolf W ^c   Van Dulken, Eric J ^b   Depla, Annekatrien C T M ^b   Cats, Annemieke ^f   Schellens, Jan H M ^c,f   Peeters, Petra H M ^a,g   Beijnen, Jos H ^b   Van Gils, Carla H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Central Hospital Pharmacy   (Netherlands)

^e Sittard Geleen Heerlen   (Netherlands)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

biomarkers; breast cancer; early diagnosis; LC MS MS; proteomics; quantification

Indexed keywords

BRADYKININ; BRADYKININ DERIVATIVE; BRADYKININ[1-8]; COMPLEMENT COMPONENT C4A; DEGRADOME; EXOPEPTIDASE; FIBRINOGEN A ALPHA CHAIN; FIBRINOGEN VARIANT; HYP 3 BRADYKININ; INTERALPHA TRYPSIN INHIBITOR HEAVY CHAIN 4; PROTEOME; TRYPSIN INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD STORAGE; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; SAMPLE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

AGED; AMINO ACID SEQUENCE; AREA UNDER CURVE; BLOOD PROTEINS; BRADYKININ; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; COMPLEMENT C4A; FEMALE; FIBRINOGEN; GLYCOPROTEINS; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NETHERLANDS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 77955434562     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100395s     Document Type: Article

References (31)

1. Barros, A. C.; Fry, W., Jr.; Nazario, A. C.; Santos, M. O.; Sato, M. K. Experience with CA 15.3 as a tumor marker in breast cancer Eur. J. Surg. Oncol. 1994, 20, 130-133
2. Eskelinen, M.; Kataja, V. Hamalainen E; Kosma VM; Penttila I; Alhava E. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer Anticancer Res. 1997, 17, 1231-1234
3. Fabre-Lafay, S.; Monville, F.; Garrido-Urbani, S.; Berruyer-Pouyet, C.; Ginestier, C.; Reymond, N.; Finetti, P.; Sauvan, R.; Adelaide, J.; Geneix, J.; Lecocq, E.; Popovici, C.; Dubreuil, P.; Viens, P.; Goncalves, A.; Charafe-Jauffret, E.; Jacquemier, J.; Birnbaum, D.; Lopez, M. Nectin-4 is a new histological and serological tumor associated marker for breast cancer BMC Cancer 2007, 7, 73
4. Rodriguez de, P. L.; Arnaiz, F.; Estenoz, J.; Ortuno, B.; Lanzos, E. Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma Int. J. Biol. Markers 1995, 10, 24-29
5. Gast, M. C.; Schellens, J. H.; Beijnen, J. H. Clinical proteomics in breast cancer: a review Breast Cancer Res. Treat. 2009, 116, 17-29
6. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; Bast, R. C., Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J. Clin. Oncol. 2007, 25, 5287-5312 (Pubitemid 350232263)
7. Belluco, C.; Petricoin, E. F.; Mammano, E.; Facchiano, F.; Ross-Rucker, S.; Nitti, D.; Maggio, C. D.; Liu, C.; Lise, M.; Liotta, L. A.; Whiteley, G. Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer Ann. Surg. Oncol. 2007, 14, 2470-2476
8. Gast, M. C.; Bonfrer, J. M.; van Dulken, E. J.; de Kock, L.; Rutgers, E. J.; Schellens, J. H.; Beijnen, J. H. SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity Cancer Biomark. 2006, 2, 235-248
9. Li, J.; Zhang, Z.; Rosenzweig, J.; Wang, Y. Y.; Chan, D. W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer Clin. Chem. 2002, 48, 1296-1304
10. Li, J.; Orlandi, R.; White, C. N.; Rosenzweig, J.; Zhao, J.; Seregni, E.; Morelli, D.; Yu, Y.; Meng, X. Y.; Zhang, Z.; Davidson, N. E.; Fung, E. T.; Chan, D. W. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry Clin. Chem. 2005, 51, 2229-2235
11. Mathelin, C.; Cromer, A.; Wendling, C.; Tomasetto, C.; Rio, M. C. Serum biomarkers for detection of breast cancers: a prospective study Breast Cancer Res. Treat. 2006, 96, 83-90
12. van Winden, A. W.; Gast, M. C.; Beijnen, J. H.; Rutgers, E. J.; Grobbee, D. E.; Peeters, P. H.; van Gils, C. H. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study BMC Med. Genomics 2009, 2, 4
13. Hu, Y.; Zhang, S.; Yu, J.; Liu, J.; Zheng, S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer Breast 2005, 14, 250-255
14. Vlahou, A.; Laronga, C.; Wilson, L.; Gregory, B.; Fournier, K.; McGaughey, D.; Perry, R. R.; Wright, G. L., Jr.; Semmes, O. J. A novel approach toward development of a rapid blood test for breast cancer Clin. Breast Cancer. 2003, 4, 203-209
15. van der Werff, M. P.; Mertens, B.; de Noo, M. E.; Bladergroen, M. R.; Dalebout, H. C.; Tollenaar, R. A.; Deelder, A. M. Case-control breast cancer study of MALDI-TOF proteomic mass spectrometry data on serum samples Stat. Appl. Genet. Mol. Biol. 2008, 7, Article2
16. Engwegen, J. Y.; Gast, M. C.; Schellens, J. H.; Beijnen, J. H. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry Trends Pharmacol. Sci. 2006, 27, 251-259
17. Fung, E. T.; Yip, T. T.; Lomas, L.; Wang, Z.; Yip, C.; Meng, X. Y.; Lin, S.; Zhang, F.; Zhang, Z.; Chan, D. W.; Weinberger, S. R. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays Int. J. Cancer 2005, 115, 783-789
18. Villanueva, J.; Shaffer, D. R.; Philip, J.; Chaparro, C. A.; Erdjument-Bromage, H.; Olshen, A. B.; Fleisher, M.; Lilja, H.; Brogi, E.; Boyd, J.; Sanchez-Carbayo, M.; Holland, E. C.; Cordon-Cardo, C.; Scher, H. I.; Tempst, P. Differential exoprotease activities confer tumor-specific serum peptidome patterns J. Clin. Invest. 2006, 116, 271-284
19. van den Broek, I; Sparidans, R. W.; Schellens, J. H. M.; Beijnen, J. H. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2010, 878, 590-602
20. U.S. Food and Drug Administration: Centre for Drug Evaluation and Research. Guidance for Industry: Bioanalytical Method Validation. Available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM070107.pdf; accessed October 2009.
21. Banks, R. E.; Stanley, A. J.; Cairns, D. A.; Barrett, J. H.; Clarke, P.; Thompson, D.; Selby, P. J. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry Clin. Chem. 2005, 51, 1637-1649
22. Gast, M. C.; van Gils, C. H.; Wessels, L. F.; Harris, N.; Bonfrer, J. M.; Rutgers, E. J.; Schellens, J. H.; Beijnen, J. H. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS) Clin. Chem. Lab Med. 2009, 47, 694-705
23. Engwegen, J. Y.; Alberts, M.; Knol, J. C.; Jimenez, C. R.; Depla, A. C.; Tuynman, H.; Snel, P.; Smits, M. E.; Cats, A.; Schellens, J. H.; Beijnen, J. H. Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer Proteomics Clin. Appl. 2008, 2, 936-945
24. Timms, J. F.; Arslan-Low, E.; Gentry-Maharaj, A.; Luo, Z.; T'Jampens, D.; Podust, V. N.; Ford, J.; Fung, E. T.; Gammerman, A.; Jacobs, I.; Menon, U. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles Clin. Chem. 2007, 53, 645-656
25. Nishimura, H.; Kakizaki, I.; Muta, T.; Sasaki, N.; Pu, P. X.; Yamashita, T.; Nagasawa, S. cDNA and deduced amino acid sequence of human PK-120, a plasma kallikrein-sensitive glycoprotein FEBS Lett. 1995, 357, 207-211
26. Davie, E. W.; Fujikawa, K. Basic mechanisms in blood coagulation Annu. Rev. Biochem. 1975, 44, 799-829
27. Marshall, P.; Heudi, O.; McKeown, S.; Amour, A.; bou-Shakra, F. Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry Rapid Commun. Mass Spectrom. 2002, 16, 220-228
28. Belluco, C.; Petricoin, E. F.; Mammano, E.; Facchiano, F.; Ross-Rucker, S.; Nitti, D.; Maggio, C. D.; Liu, C.; Lise, M.; Liotta, L. A.; Whiteley, G. Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer Ann. Surg. Oncol. 2007, 14, 2470-2476
29. Jimenez, C. R.; Piersma, S.; Pham, T. High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery Biomark. Med. 2007, 1, 541-565
30. Engwegen, J. Y.; Depla, A. C.; Smits, M. E.; Cats, A.; Tuynman, H.; van Heukelem, H. A.; Snel, P.; Meuleman, W.; Wessels, L. F.; Schellens, J. H.; Beijnen, J. H. Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk Biomark. Insights 2008, 3, 375-385
31. National Center for Bioltechnology Information Web Site. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val= NP-000473 (Apo A-IV), NP-002209 (ITIH4), NP-009224 (C4a), NP-000499 (Fibrinogen alpha-chain); accessed October 2009.